AVHOQ yields 1255.00% · JNJ yields 2.13%● Live data
📍 AVHOQ pulled ahead of the other in Year 1
Combined, AVHOQ + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AVHOQ + JNJ for your $10,000?
Avianca Holdings S.A., together with its subsidiaries, provides passenger and cargo air transportation services in the United States, Central America and the Caribbean, Colombia, rest of South America, and internationally. The company operates in two segments, Air Transportation and Loyalty. It also offers aircraft maintenance, crew training, and other airport services to other carriers. In addition, the company provides meals and beverages, baggage handling, in-flight entertainment, and charter flight services, as well as unaccompanied minors and lounge passes; leases aircraft space for check-in counters, ticket sales facilities, VIP lounges, and back office; and engages in the marketing rebates, duty-free sales, and ticket sales activities. Further, it operates LifeMiles, a frequent flyer program. As of December 31, 2020, it operated a fleet of 146 aircraft, including 135 passenger aircraft and 11 cargo transport aircraft. The company was formerly known as AviancaTaca Holding S.A. and changed its name to Avianca Holdings S.A. in March 2013. The company was founded in 1919 and is headquartered in Bogotá, Colombia. Avianca Holdings S.A. is a subsidiary of BRW Aviation LLC. On May 10, 2020, Avianca Holdings S.A., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Full AVHOQ Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.